MIRM
VENTE TOTALE: 50 000 titres (~4 912 600,00 $ US)
- Insiders
- Peetz Christopher
- Total bought
- —
- Total sold
- $4,912,600
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-09-07
MIRM presents a constructive setup combining solid liquidity (75), improving operational fundamentals (positive EBITDA, narrowing losses), and a meaningful earnings catalyst (Q2 beat + raised 2026 guidance to $680-700M)…
The first sentence of the analysis written for MIRM on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 80.7% | 75.8% | 74.8% | 83.9% | 90.1% | |
| Ebit Margin | -1.4% | -21.6% | -79.0% | -163.6% | -346.7% | |
| Ebitda Margin | 3.3% | -14.5% | -73.2% | -159.4% | -341.7% | |
| Operating Profit Margin | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | |
| Pretax Profit Margin | -4.1% | -25.8% | -87.1% | -184.4% | -438.7% | |
| Continuous Operations Profit Margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | |
| Net Profit Margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | |
| Bottom Line Profit Margin | -4.5% | -26.1% | -87.7% | -177.2% | -438.9% | |
| Current Ratio | 2.671 | 3.104 | 4.451 | 2.939 | 3.911 | |
| Quick Ratio | 2.550 | 2.927 | 4.195 | 2.853 | 3.875 | |
| Solvency Ratio | 0.002 | -0.144 | -0.383 | -0.628 | -0.476 | |
| Cash Ratio | 1.442 | 1.758 | 3.289 | 0.433 | 0.736 | |
| Price To Earnings Ratio | -168.064 | -22.351 | -7.380 | -4.863 | -5.758 | |
| Price To Earnings Growth Ratio | 2.253 | 0.416 | 29.594 | -0.109 | 0.178 | |
| Forward Price To Earnings Growth Ratio | 2.253 | 0.416 | 29.594 | -0.109 | 0.178 | |
| Price To Earnings Diluted Ratio | -168.064 | -22.351 | -7.380 | -4.851 | -5.758 | |
| Price To Earnings Diluted Growth Ratio | 2.253 | 0.416 | 14.834 | -0.107 | 0.178 | |
| Price To Book Ratio | 12.600 | 8.709 | 4.854 | 4.646 | 4.023 | |
| Price To Sales Ratio | 7.606 | 5.833 | 6.476 | 8.563 | 25.271 | |
| Price To Free Cash Flow Ratio | 72.261 | 210.574 | -13.255 | -5.480 | -3.186 | |
| Price To Operating Cash Flow Ratio | 71.026 | 190.322 | -17.012 | -5.493 | -3.643 | |
| Debt To Assets Ratio | 0.379 | 0.474 | 0.477 | 0.006 | 0.009 | |
| Debt To Equity Ratio | 1.015 | 1.408 | 1.239 | 0.015 | 0.022 | |
| Debt To Capital Ratio | 0.504 | 0.585 | 0.553 | 0.015 | 0.021 | |
| Long Term Debt To Capital Ratio | 0.496 | 0.577 | 0.552 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.678 | 2.973 | 2.600 | 2.485 | 2.451 | |
| Working Capital Turnover Ratio | 1.709 | 1.189 | 0.875 | 0.618 | 0.112 | |
| Operating Cash Flow Ratio | 0.271 | 0.082 | -0.815 | -1.856 | -3.117 | |
| Operating Cash Flow Sales Ratio | 0.107 | 0.031 | -0.381 | -1.559 | -6.937 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.983 | 0.904 | 1.283 | 1.002 | 1.143 | |
| Debt Service Coverage Ratio | 1.061 | -3.494 | -9.102 | -7.288 | -3.719 | |
| Interest Coverage Ratio | -1.538 | -6.122 | -7.226 | -8.212 | -9.859 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.175 | 0.032 | -0.230 | -54.907 | -50.787 | |
| Capital Expenditure Coverage Ratio | 58.519 | 10.398 | -3.528 | -432.144 | -6.978 | |
| Dividend Paid And Capex Coverage Ratio | 58.519 | 10.398 | -3.528 | -432.144 | -6.978 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 231.776 | -42.072 | -9.002 | -5.161 | -6.957 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 80.7% | ▲4.9% | ▼-0.3% |
| Ebit Margin | -1.4% | ▲20.2% | ▲121.1% |
| Ebitda Margin | 3.3% | ▲17.8% | ▲120.4% |
| Operating Profit Margin | -4.2% | ▲21.8% | ▲228.8% |
| Pretax Profit Margin | -4.1% | ▲21.7% | ▲143.9% |
| Continuous Operations Profit Margin | -4.5% | ▲21.6% | ▲142.2% |
| Net Profit Margin | -4.5% | ▲21.6% | ▲142.2% |
| Bottom Line Profit Margin | -4.5% | ▲21.6% | ▲142.4% |
| Current Ratio | 2.671 | ▼-0.433 | ▼-0.744 |
| Quick Ratio | 2.550 | ▼-0.377 | ▼-0.730 |
| Solvency Ratio | 0.002 | ▲0.146 | ▲0.328 |
| Cash Ratio | 1.442 | ▼-0.317 | ▼-0.090 |
| Price To Earnings Ratio | -168.064 | ▼-145.713 | ▼-126.381 |
| Price To Earnings Growth Ratio | 2.253 | ▲1.837 | ▼-4.213 |
| Forward Price To Earnings Growth Ratio | 2.253 | ▲1.837 | ▼-4.213 |
| Price To Earnings Diluted Ratio | -168.064 | ▼-145.713 | ▼-126.383 |
| Price To Earnings Diluted Growth Ratio | 2.253 | ▲1.837 | ▼-1.262 |
| Price To Book Ratio | 12.600 | ▲3.891 | ▲5.634 |
| Price To Sales Ratio | 7.606 | ▲1.773 | ▼-3.144 |
| Price To Free Cash Flow Ratio | 72.261 | ▼-138.313 | ▲20.078 |
| Price To Operating Cash Flow Ratio | 71.026 | ▼-119.296 | ▲23.986 |
| Debt To Assets Ratio | 0.379 | ▼-0.095 | ▲0.110 |
| Debt To Equity Ratio | 1.015 | ▼-0.393 | ▲0.275 |
| Debt To Capital Ratio | 0.504 | ▼-0.081 | ▲0.168 |
| Long Term Debt To Capital Ratio | 0.496 | ▼-0.081 | ▲0.171 |
| Financial Leverage Ratio | 2.678 | ▼-0.294 | ▲0.041 |
| Working Capital Turnover Ratio | 1.709 | ▲0.520 | ▲0.808 |
| Operating Cash Flow Ratio | 0.271 | ▲0.190 | ▲1.358 |
| Operating Cash Flow Sales Ratio | 0.107 | ▲0.076 | ▲1.855 |
| Free Cash Flow Operating Cash Flow Ratio | 0.983 | ▲0.079 | ▼-0.080 |
| Debt Service Coverage Ratio | 1.061 | ▲4.555 | ▲5.569 |
| Interest Coverage Ratio | -1.538 | ▲4.583 | ▲5.053 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.175 | ▲0.142 | ▲21.318 |
| Capital Expenditure Coverage Ratio | 58.519 | ▲48.121 | ▲133.266 |
| Dividend Paid And Capex Coverage Ratio | 58.519 | ▲48.121 | ▲133.266 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 231.776 | ▲273.847 | ▲198.059 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.97B | $1.97B | $1.21B | $659.9M | $483.6M | |
| Enterprise value | $3.99B | $2.06B | $1.23B | $634.0M | $454.9M | |
| EV / Sales | 7.65x | 6.12x | 6.59x | 8.23x | 23.77x | |
| EV / Op. cash flow | 71.43x | 199.55x | -17.32x | -5.28x | -3.43x | |
| EV / Free cash flow | 72.68x | 220.78x | -13.49x | -5.27x | -3.00x | |
| EV / EBITDA | 231.78x | -42.07x | -9.00x | -5.16x | -6.96x | |
| Net debt / EBITDA | 1.32x | -1.95x | -0.16x | 0.21x | 0.44x | |
| Current ratio | 2.67x | 3.10x | 4.45x | 2.94x | 3.91x | |
| Income quality | -2.39x | -0.12x | 0.43x | 0.89x | 1.58x | |
| Graham net-net | -$1 | -$2 | -$1 | -$1 | -$0 | |
| Tax burden | 109.0% | 101.2% | 100.6% | 95.5% | 100.0% | |
| Interest burden | 304.4% | 119.7% | 110.3% | 112.7% | 126.5% | |
| Working capital | $343.9M | $266.2M | $300.5M | $125.5M | $124.0M | |
| Invested capital | $615.4M | $525.9M | $555.4M | $186.8M | $145.3M | |
| Return on assets | -2.8% | -13.1% | -25.3% | -38.4% | -28.5% | |
| Operating ROA | -2.9% | -13.3% | -21.8% | -40.5% | -64.8% | |
| Return on tangible assets | -4.0% | -20.9% | -41.5% | -46.2% | -30.4% | |
| Return on equity | -7.4% | -39.0% | -65.7% | -95.5% | -69.9% | |
| Return on invested capital | -3.5% | -16.0% | -19.5% | -43.3% | -68.6% | |
| Return on capital employed | -3.5% | -16.1% | -19.5% | -45.5% | -68.8% | |
| Earnings yield | -0.6% | -4.5% | -13.5% | -20.6% | -17.4% | |
| Free cash flow yield | 1.4% | 0.5% | -7.5% | -18.2% | -31.4% | |
| Capex / Op. cash flow | 1.7% | 9.6% | -28.3% | -0.2% | -14.3% | |
| Capex / Depreciation | 3.9% | 4.2% | 185.7% | 7.6% | 1951.2% | |
| Capex / Sales | 0.2% | 0.3% | 10.8% | 0.4% | 99.4% | |
| SG&A / Sales | 49.3% | 60.0% | 78.3% | 115.6% | 309.4% | |
| R&D / Sales | 35.7% | 41.7% | 55.1% | 138.6% | 686.7% | |
| Stock comp / Sales | 13.7% | 14.4% | 18.8% | 35.0% | 120.6% | |
| Intangibles / Total assets | 31.0% | 37.2% | 39.1% | 16.7% | 6.4% | |
| Days sales outstanding | 86d | 85d | 133d | 114d | 83d | |
| Days payables outstanding | 35d | 65d | 58d | 256d | 1758d | |
| Operating cycle | 177d | 185d | 306d | 278d | 373d | |
| Cash conversion cycle | 142d | 120d | 249d | 21d | -1385d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+101.8%EV / Sales ▲+25.1%EV / EBITDA ▲+650.9%EV / Op. cash flow ▼-128.115Earnings yield ▲+0.039
Profitability
Return on equity ▲+0.316Return on assets ▲+0.103Return on invested capital ▲+0.126Return on capital employed ▲+0.126Operating ROA ▲+0.104Income quality ▼-2.272Tax burden ▲+0.079
Efficiency
Days sales outstanding ▲+1.532Days payables outstanding ▼-30.465Operating cycle ▼-8.315Cash conversion cycle ▲+22.150Capex / Sales ▼-0.001R&D / Sales ▼-0.060
Balance-sheet strength
Current ratio ▼-0.433Net debt / EBITDA ▲+3.269Working capital ▲+77648000.000Invested capital ▲+89539000.000Intangibles / Total assets ▼-0.063
Change over 5 years
Valuation
Market cap ▲+719.9%EV / Sales ▼-67.8%EV / EBITDA ▲+3431.4%EV / Op. cash flow ▲+74.860Earnings yield ▲+0.168
Profitability
Return on equity ▲+0.624Return on assets ▲+0.257Return on invested capital ▲+0.651Return on capital employed ▲+0.653Operating ROA ▲+0.618Income quality ▼-3.970Tax burden ▲+0.090
Efficiency
Days sales outstanding ▲+3.063Days payables outstanding ▼-1723.174Operating cycle ▼-196.824Cash conversion cycle ▲+1526.350Capex / Sales ▼-0.992R&D / Sales ▼-6.510
Balance-sheet strength
Current ratio ▼-1.240Net debt / EBITDA ▲+0.884Working capital ▲+219889000.000Invested capital ▲+470123000.000Intangibles / Total assets ▲+0.246
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-04 Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What''s next for the stock?
- 2026-09-02 Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
- 2026-08-25 BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRM BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,390,063 shares of the company''s stock, valued at approximately $513,945,000. BlackRock Inc. owned about 7.20% of Mirum Pharmaceuticals at the end
- 2026-08-24 Deutsche Bank AG Purchases New Holdings in Mirum Pharmaceuticals, Inc. $MIRM Deutsche Bank AG acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 81,586 shares of the company''s stock, valued at approximately $9,551,000. Deutsche Bank AG owned 0.13% of Mirum Pharmaceuticals at the end
- 2026-08-11 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
- 2026-08-06 Mirum''s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
- 2026-08-05 Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
- 2026-08-05 Mirum Pharmaceuticals Q2 Earnings Call Highlights Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.
- 2026-08-05 Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 2026-08-05 Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.12 per share a year ago.